Dosing and uses of Condylox (podofilox)
Adult dosage forms and strengths
topical solution/geL
- 0.5%
Anogenital Warts
Apply with cotton-tipped applicator (solution) or finger (gel) q12hr for 3 days then no treatment for 4 days
May repeat in 1 week, cycle up to 4 times
Pediatric dosage forms and strengths
Safety & efficacy not established
Condylox (podofilox) adverse (side) effects
>10%
Mild to moderate inflammation (63%)
Mild to moderate burning (63%)
Mild to moderate erosion (44-48%)
Mild to moderate pain (44-48%)
Mild to moderate pruritus (44-48%)
Mild to moderate bleeding (22%)
1-10%
Stinging (7%)
Erythema (5%)
Severe inflammation (8-12%)
Severe burning (8-12%)
Severe erosion (8-12%)
Severe pain (8-12%)
Severe pruritus (8-12%)
Headache (6-9%)
Insomnia
Dizziness
Hematuria
Nausea
Vomiting (5%)
Severe bleeding (1%)
Warnings
Contraindications
Hypersensitivity
Pregnancy and lactation
Pregnancy category: C
Lactation: not known whether topically applied podofilox is distributed into human milk; potential for serious adverse reactions in nursing infants
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Condylox (podofilox)
Half-Life: 1-4.5 hr
Absorption: little systemic
Mechanism of action
Antimitotic agent from plant families Coniferae and Berberidaceae
Interference with microtubular function of the keratinocytes contained in the warts and local vascular structures; local immunomodulating effects
